Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.25 EUR
Change Today -1.24 / -1.98%
Volume 4.1K
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 10:14 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€61.73
Previous Close
€62.49
Day High
€62.12
Day Low
€60.78
52 Week High
04/23/15 - €69.06
52 Week Low
08/11/14 - €50.88
Market Cap
77.4B
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/15
P/E TM
--
Dividend
€3.04
Dividend Yield
4.25%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (ZEG) Key Developments

AstraZeneca PLC Board Recommends First Interim Dividend for 2015, Payable on 14 September 14, 2015; Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

AstraZeneca PLC Board recommended an unchanged first interim dividend of $0.90. The record date for the first interim dividend for 2015, payable on September 14, 2015, will be August 14, 2015. Ordinary Shares listed in London and Stockholm will trade ex-dividend from August 13, 2015. American Depositary Shares listed in New York will trade ex-dividend from August 12, 2015. The company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, on reported basis, revenue was $6,307 million against $6,762 million a year ago. Operating profit was $923 million against $1,109 million a year ago. Profit before tax was $658 million against $866 million a year ago. Profit for the period was $696 million against $797 million a year ago. Profit attributable to the owners of the parent was $697 million against $796 million a year ago. Earnings per $0.25 ordinary share were $0.55 against $0.63 per basic and diluted share a year ago. On core basis, operating profit was $1,813 million against $2,031 million for the same period in the last year. Profit before tax was $1,679 million against $1,890 million for the same period in the last year. Profit after tax was $1,520 million against $1,643 million for the same period in the last year. Net profit was $1,520 million against $1,642 million for the same period in the last year. Earnings per share were $1.21 against $1.30 for the same period in the last year. For the six months, on reported basis, revenue was $12,364 million against $13,222 million for the same period in the last year. Operating profit was $1,856 million against $1,945 million for the same period in the last year. Profit before tax was $1,336 million against $1,504 million for the same period in the last year. Profit for the period was $1,248 million against $1,303 million for the same period in the last year. Profit attributable to owners of the parent was $1,247 million against $1,300 million for the same period in the last year. Diluted earnings per $0.25 Ordinary Share was $0.99 against $1.03 for the same period in the last year. Net cash inflow from operating activities was $1,008 million against $3,266 million for the same period in the last year. Purchase of property, plant and equipment was $497 million against $378 million for the same period in the last year. Purchase of intangible assets was $1,222 million against $1,490 million for the same period in the last year. Net debt as at June 30, 2015 was $5,994 million against $2,500 million a year ago. On core basis, operating profit was $3,618 million against $3,983 million for the same period in the last year. Profit before tax was $3,361 million against $3,716 million for the same period in the last year. Profit attributable to owners of the parent was $2,888 million against $3,113 million for the same period in the last year. Earnings per share were $2.29 against $2.47 for the same period in the last year. The company revised its total revenue guidance at CER from that provided on April 24, 2015. Total revenue in the full year is now expected to decline by low single-digit percent versus the prior guidance of a mid single-digit decline. Core EPS guidance at CER for the year is unchanged and Core EPS is expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D.

AstraZeneca Enters into a Definitive Agreement with Genzyme to Divest Caprelsa

AstraZeneca announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa (Registered) (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, with global product sales of $48 million in 2014. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300 million, including an upfront payment of $165 million to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. As an asset divestment, upfront receipt and any subsequent payments will be reported in Other Operating Income in the Company's financial statements.

Fujifilm Kyowa Kirin Biologics Co. Ltd. Establishes Joint Venture with AstraZeneca plc to Develop and Commercialize Anti-Vegf Biosimilar

Fujifilm Kyowa Kirin Biologics Co. Ltd. announced that it has entered into an agreement with AstraZeneca plc to establish a joint venture for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours. FKB238 is a biosimilar version of bevacizumab, an anti-VEGF1 humanized monoclonal antibody with established efficacy across a range of cancers including colorectal and non-small cell lung cancer2. Fujifilm Kyowa Kirin Biologics commenced its Phase I clinical trial for FKB238 in Europe in November 2014. Under the terms of the agreement, the new joint venture that is equally co-funded by the two companies and will use FKB238s non-clinical, clinical development data compiled by Fujifilm Kyowa Kirin Biologics thus far. Fujifilm Kyowa Kirin Biologics will transfer the rights to FKB238 to the new joint venture, and will receive a lump-sum payment of USD 45 million in return.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €61.25 EUR -1.24

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $151.34 USD -0.23
Abbott Laboratories $50.69 USD -0.08
Biogen Inc $318.78 USD +1.78
Eli Lilly & Co $84.51 USD -0.03
Valeant Pharmaceuticals International Inc C$335.61 CAD +4.75
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 72.1x
Price/Sales 3.3x
Price/Book 4.7x
Price/Cash Flow 72.2x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.